Standardize Clinical Medication and Improve Maternal and Neonatal Outcomes: Interpretation on Prevention of Group B Streptococcal Early-onset Disease in Newborns: ACOG Committee Opinion, Number 797

Colonization of Group B streptococcus (GBS) in the reproductive tract and mother-to-child transmission is an important cause of puerperal infection and neonatal infection/death. Currently, there is no unified screening strategy in China, and most medical institutions adopt the guideline of Prevention of perinatal group B streptococcal disease that formulated by the U.S. Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists (ACOG) in 2010. The incidence of GBS related diseases has been reduced significantly. In January 2020, ACOG released a new consensus on GBS screening and intrapartum management:Prevention of Group B Streptococcal Early-Onset Disease in Newborns:ACOG Committee Opinion, Number 797, which updated issues such as timing and procedure for preterm GBS screening andintrapartum antibiotic prophylaxis. Here we present a detailed interpretation on the relevant content.